IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival

Cell Death and Disease

Volumn 5, Issue 6, 2014, Pages

  Verhagen, H J M P ^a   De Leeuw, D C ^a   Roemer, M G M ^a   Denkers, F ^a   Pouwels, W ^a   Rutten, A ^a   Celie, P H ^b   Ossenkoppele, G J ^a   Schuurhuis, G J ^a   Smit, L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DOXORUBICIN; ETOPOSIDE; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SOMATOMEDIN 1 RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; SOMATOMEDIN C RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MEMBRANE; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; TUMOR XENOGRAFT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HL 60 CELL LINE; K562 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MORTALITY; PATHOLOGY;

APOPTOSIS; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; TUMOR SUPPRESSOR PROTEINS;

EID: 84903768850     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.268     Document Type: Article

References (46)

1. Löwenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008; 1-11.
2. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273-3287.
3. He Y, Zhang J, Zheng J, Du W, Xiao H, LiuWet al. The insulin-like growth factor-1 receptor kinase inhibitor, NVP-ADW742, suppresses survival and resistance to chemotherapy in acute myeloid leukemia cells. Oncol Res 2010; 19: 35-43.
4. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-167.
5. Khandwala HM, Mc Cutcheon IE, Flyvbjerg A, Friend KE. The effect of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244.
6. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, De Angelis T et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994; 7: 4588-4595.
7. Wu Y, Cui K, Miyoshi K, Henninghausen L, Green JE, Setser J et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003; 63: 4384-4388.
8. Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997; 8: 71-92.
9. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856-2861.
10. Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García- Echeverría C et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008; 141: 470-482.
11. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
12. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007; 21: 1921-1930.
13. Estrov Z, Meir R, Barak Y, Zaizov R, Zadik Z. Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts. J Clin Oncol 1991; 9: 394-399.
14. Frostad S, Bruserud O. In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. Eur J Haematol 1999; 62: 191-198.
15. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21: 886-896.
16. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2012; 95: 415-423.
17. Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y et al. Increased expression of insulin-like growth factor is associated with Ara-C resistance in leukemia. Exp Med 2006; 209: 217-228.
18. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
19. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008; 68: 8322-8332.
20. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62: 200-207.
21. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulinlike growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957.
22. Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquiè res G, Wolf-Kümmeth S et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009; 69: 2996-3003.
23. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor-binding proteins. Endocr Rev 2002; 23: 824-854.
24. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulus DD, Seth AK. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 2005; 41: 1515-1527.
25. Hwa V, Oh Y, Rosenfeld G. The insulin-like growth factor binding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-787.
26. Sato Y, Chen Z, Miyazaki K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci 2007; 98: 1055-1063.
27. Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by Insulin-like growth factors. Sci Signal 2012; 5: 1-11.
28. Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer 2012; 130: 319-327.
29. Okamura J, Huang Y, Moon D, Brait M, Chang X, Kim MS. Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer. Cancer Biol Ther 2012; 13: 148-155.
30. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483: 570-575.
31. Benatar T, Yang W, Amemiya Y, Evdokimova H, Kahn C, Holloway A et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. 2012. Breast Cancer Res Treat 2012; 133: 563-573.
32. Chen RY, Chen HX, Jian P, Xu L, Li J, Fan YM et al. Intratumoral injection of pEGFC1-IGFBP7 inhibits malignant melanoma growth in C57BL/6J mice by inducing apoptosis and down-regulating VEGF expression. Oncol Rep 2010; 4: 981-988.
33. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Role for IGFBP7 in senescence induction by BRAF. Cell 2010; 141: 746-747.
34. Severino V, Alessio N, Farina A, Sandomenico A, Cipollaro M, Peluso G et al. Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells. Cell Death Dis 2013; 4: e911.
35. García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541; A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
36. García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008; 141: 470-482.
37. Akaogi K, Sato J, Okabe Y, Sakamoto Y, Yasumitsu H, Miyazaki K. Synergistic growth stimulation of mouse fibroblasts by tumor-derived adhesion factor with insulin-like growth factors and insulin. Cell Growth Differ 1996; 7: 1671-1677.
38. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
39. Ley D, Guzman CX, Adolfsson KH, Scott AM, Braunschweig AB et al. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
40. Hu S, Chen R, Man X, Feng X, Cen J et al. Function and expression of insulin-like growth factor-binding protein 7 (IGFBP7) gene in childhood acute myeloidleukemia. Pediatr Hematol Oncol 2011; 28: 279-287.
41. Holohan C, Schaeybroeck van S, Longley DB, Johnson PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13: 714-726.
42. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL et al. Phosphorylated insulinlike growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68: 10238-10246.
43. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012; 132: 131-142.
44. Leal SM, Huang SS, Huang JS. Interactions of high affinity insulin-like growth factorbinding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem 1999; 274: 6711-6717.
45. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 1998; 273: 18347-18352.
46. Darr J, Klochendler A, Isaac S, Eden A. Loss of IGFBP7 expression and persistent Akt activation contribute to SMARCCB1/Snf5-mediated tumorigenesis. Oncogene 2013; 261: doi:10.1038/onc.2013.261.